The European Commission issued marketing authorization approval for Halaven (eribulin) for locally advanced or metastatic breast cancer that has progressed after at least one chemotherapeutic regimen for advanced disease.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
